nach oben

Current Cardiology Reports

Erschienen in:

11.10.2023 | Women and Cardiovascular Health (N Goldberg and S Lewis, Section Editors)

Tailored to a Woman’s Heart: Gender Cardio-Oncology Across the Lifespan

verfasst von: Ming Hui Chen, Sonia F. Epstein

Erschienen in: Current Cardiology Reports | Ausgabe 11/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Females outnumber males among long-term cancer survivors, primarily as a result of the prevalence of breast cancer. Late cardiovascular effects of cancer develop over several decades, which for many women, may overlap with reproductive and lifecycle events. Thus, women require longitudinal cardio-oncology care that anticipates and responds to their evolving cardiovascular risk.

Recent Findings

Women may experience greater cardiotoxicity from cancer treatments compared to men and a range of treatment-associated hormonal changes that increase cardiometabolic risk. Biological changes at critical life stages, including menarche, pregnancy, and menopause, put female cancer patients and survivors at a unique risk of cardiovascular disease. Women also face distinct psychosocial and physical barriers to accessing cardiovascular care.

Summary

We describe the need for a lifespan-based approach to cardio-oncology for women. Cardio-oncology care tailored to women should rigorously consider cancer treatment/outcomes and concurrent reproductive/hormonal changes, which collectively shape quality of life and cardiovascular outcomes.

American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2022–2024. Atlanta: American Cancer Society. 2022.

Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, Kramer J, Siegel RL. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72(5):409–36. https://doi.org/10.3322/caac.21731.CrossRefPubMed

Chen MH, Colan SD, Diller L. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers. Circ Res. 2011;108(5):619–28. https://doi.org/10.1161/CIRCRESAHA.110.224519.CrossRefPubMed

Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889–97. https://doi.org/10.1093/eurheartj/ehz766.CrossRefPubMedCentralPubMed

Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation. 2011;124:2145–54. https://doi.org/10.1161/CIRCULATIONAHA.110.968792.CrossRefPubMedCentralPubMed

Jarvie JL, Foody JM. Recognizing and improving health care disparities in the prevention of cardiovascular disease in women. Curr Cardiol Rep. 2010;12:488–96. https://doi.org/10.1007/s11886-010-0135-4.CrossRefPubMed

Wilkinson C, Bebb O, Dondo TB, et al. Sex differences in quality indicator attainment for myocardial infarction: a nationwide cohort study. Heart. 2019;105:516–23. https://doi.org/10.1136/heartjnl-2018-313959.CrossRefPubMed

Bucholz EM, Normand SL, Wang Y, Ma S, Lin H, Krumholz HM. Life expectancy and years of potential life lost after acute myocardial infarction by sex and race: a cohort-based study of medicare beneficiaries. J Am Coll Cardiol. 2015;66(6):645–55. https://doi.org/10.1016/j.jacc.2015.06.022.CrossRefPubMedCentralPubMed

• Canale ML, Bisceglia I, Gallucci G, Russo G, Camerini A, Di Fusco SA, et al. Women at heart: Introducing gender cardio-oncology. Front Cardiovasc Med. 2022;9:974123. https://doi.org/10.3389/fcvm.2022.974123. Reviews relevant cancer-related cardiovascular issues in women, especially in pregnant, young and old populations, and discusses importance of a life-course approach.

10.

• Simek S, Lue B, Rao A, Ravipati G, Vallabhaneni S, Zhang K, et al. Gender differences in diagnosis, prevention, and treatment of cardiotoxicity in cardio-oncology. J Clin Med. 2022;11(17):5167. https://doi.org/10.3390/jcm11175167. Summarizes sex- and gender-based factors related to susceptibility to cancer, cardiotoxicity, and poor cardiovascular outcomes, including psychosocial and socioeconomic factors.

11.

•• Addison D, Branch M, Baik AH, Fradley MG, Okwuosa T, Reding KW, et al. American Heart Association Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine; Council on Cardiovascular and Stroke Nursing; Council on Lifelong Congenital Heart Disease and Heart Health in the Young; and the Council on Cardiovascular Radiology and Intervention. Equity in cardio-oncology care and research: a scientific statement from the American Heart Association. Circulation. 2023;148(3):297–308. https://doi.org/10.1161/CIR.0000000000001158. Consensus statement describes evidence for cardiotoxicity disparities and proposes methodological approaches to mitigate inequity in research and clinical practice.

12.

• Wilcox NS, Rotz SJ, Mullen M, Song EJ, Ky Hamilton B, Moslehi J, et al. Sex-specific cardiovascular risks of cancer and its therapies. Circ Res. 2022;130(4):632–51. https://doi.org/10.1161/CIRCRESAHA.121.319901. Summarizes sex-based differences in epidemiology and pathophysiology of cardiotoxicity related to with anthracyclines, hematopoietic stem cell transplant, hormone therapy, and immune therapy.

13.

• Ohman RE, Yang EH, Abel ML. Inequity in cardio-oncology: identifying disparities in cardiotoxicity and links to cardiac and cancer outcomes. J Am Heart Assoc. 2021;10(24):e023852. https://doi.org/10.1161/JAHA.121.023852. Review of 15 studies discussing racial, socioeconomic, and sex- and gender-based disparities in cardiac outcomes in cancer survivors.

14.

Armstrong GT, Liu Q, Yasui Y, Neglia JP, Leisenring W, Robison LL, Mertens AC. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27(14):2328–38. https://doi.org/10.1200/JCO.2008.21.1425.CrossRefPubMedCentralPubMed

15.

Chow EJ, Chen Y, Hudson MM, Feijen EAM, Kremer LC, Border WL, et al. Prediction of ischemic heart disease and stroke in survivors of childhood cancer. J Clin Oncol. 2018;36(1):44–52.CrossRefPubMed

16.

Williams LA, Richardson M, Marcotte EL, Poynter JN, Spector LG. Sex ratio among childhood cancers by single year of age. Pediatr Blood Cancer. 2019;66(6):e27620. https://doi.org/10.1002/pbc.27620.

17.

Miller KD, Fidler-Benaoudia M, Keegan TH, Hipp HS, Jemal A, Siegel RL. Cancer statistics for adolescents and young adults, 2020. CA Cancer J Clin. 2020;70(6):443–59. https://doi.org/10.3322/caac.21637. Epub 2020 Sep 17 PMID: 32940362.CrossRefPubMed

18.

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. https://doi.org/10.3322/caac.21763.CrossRefPubMed

19.

Gernaat SAM, Boer JMA, van den Bongard DHJ, Maas AHEM, van der Pol CC, Bijlsma RM, et al. The risk of cardiovascular disease following breast cancer by Framingham risk score. Breast Cancer Res Treat. 2018;170(1):119–27. https://doi.org/10.1007/s10549-018-4723-0.CrossRefPubMedCentralPubMed

20.

Raychaudhuri S, Dieli-Conwright CM, Cheng RK, Barac A, Reding KW, Vasbinder A, et al. A review of research on the intersection between breast cancer and cardiovascular research in the Women’s Health Initiative (WHI). Front Oncol. 2023;21(12):1039246. https://doi.org/10.3389/fonc.2022.1039246.CrossRef

21.

• Barish R, Lynce F, Unger K, Barac A. Management of cardiovascular disease in women with breast cancer. Circulation. 2019;139(8):1110–20. https://doi.org/10.1161/CIRCULATIONAHA.118.039371. Summarizes professional society recommendations for breast cancer patients at risk for treatment-related cardiotoxicity.

22.

Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al.; American Heart Association Cardiovascular Disease in Women and Special Populations Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018;137(8):e30-e66. https://doi.org/10.1161/CIR.0000000000000556.

23.

• Parashar S, Akhter N, Paplomata E, et al. Cancer treatment-related cardiovascular toxicity in gynecologic malignancies. J Am Coll Cardiol CardioOnc. 2023;5(2):159–73. https://doi.org/10.1016/j.jaccao.2023.02.002. Comprehensive overview of therapies used in gynecologic malignancies, associated cardiotoxicities, risk factors for cardiotoxicity, and prevention strategies.

24.

Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, et al. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); Document Reviewers. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017;19(1):9–42. https://doi.org/10.1002/ejhf.654.

25.

McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017;31(1):63–75. https://doi.org/10.1007/s10557-016-6711-0.CrossRefPubMedCentralPubMed

26.

Meiners B, Shenoy C, Zordoky BN. Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity. Biol Sex Differ. 2018;9(1):38. https://doi.org/10.1186/s13293-018-0198-2.CrossRefPubMedCentralPubMed

27.

Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol. 1997;15(4):1544–52. https://doi.org/10.1200/JCO.1997.15.4.1544.CrossRefPubMed

28.

Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738–43.CrossRefPubMed

29.

Silber JH, Jakacki RI, Larsen RL, Goldwein JW, Barber G. Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol. 1993;21(7):477–9. https://doi.org/10.1002/mpo.2950210704.CrossRefPubMed

30.

Smitherman AB, Wood WA, Mitin N, Ayer Miller VL, Deal AM, Davis IJ, et al. Accelerated aging among childhood, adolescent, and young adult cancer survivors is evidenced by increased expression of p16INK4a and frailty. Cancer. 2020;126(22):4975–83. https://doi.org/10.1002/cncr.33112. Epub 2020 Aug 24.CrossRefPubMed

31.

•• Neilan TG, Quinaglia T, Onoue T, Mahmood SS, Drobni ZD, Gilman HK, et al. Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial. JAMA. 2023;330(6):528–36. https://doi.org/10.1001/jama.2023.11887. Double-blind randomized clinical trial at nine academic medical centers among 300 lymphoma patients finds atorvastatin reduces LVEF decline in those treated with anthracyclines.

32.

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med. 2001; 344:783–792. https://doi.org/10.1056/NEJM200103153441101.

33.

Mohan N, Jiang J, Dokmanovic M, Wu WJ. Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers. Antib Ther. 2018;1(1):13–7. https://doi.org/10.1093/abt/tby003.CrossRefPubMedCentralPubMed

34.

Dang CT, Yu AF, Jones LW, et al. Cardiac surveillance guidelines for trastuzumab-containing therapy in early-stage breast cancer: getting to the heart of the matter. J Clin Oncol. 2016;34:1030–3. https://doi.org/10.1200/JCO.2015.64.5515.CrossRefPubMedCentralPubMed

35.

Pirš B, Škof E, Smrkolj V, Smrkolj Š. Overview of immune checkpoint inhibitors in gynecological cancer treatment. Cancers (Basel). 2022;14(3):631. https://doi.org/10.3390/cancers14030631.CrossRefPubMed

36.

Zamami Y, Niimura T, Okada N, Koyama T, Fukushima K, Izawa-Ishizawa Y, Ishizawa K. Factors associated with immune checkpoint inhibitor-related myocarditis. JAMA Oncol. 2019;5:1635–7. https://doi.org/10.1001/jamaoncol.2019.3113.CrossRefPubMedCentralPubMed

37.

Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, et al. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol. 2018;19:737–46.CrossRefPubMed

38.

Grouthier V, Lebrun-Vignes B, Glazer AM, Touraine P, Funck-Brentano C, Pariente A, et al. Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. Heart. 2018;104:1859–63. https://doi.org/10.1136/heartjnl-2017-312934.CrossRefPubMed

39.

• Okwuosa TM, Morgans A, Rhee J-W, Reding KW, Maliski S, Plana J-C, et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association.Circ Genom Precis Med. 2021; 14:e000082. https://doi.org/10.1161/HCG.0000000000000082 . Consensus statement describing risks related to hormonal therapies with proposed approach to preventing adverse cardiovascular outcomes.

40.

Khosrow-Khavar F, Filion KB, Al-Qurashi S, Torabi N, Bouganim N, Suissa S, Azoulay L. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2017;28(3):487–96. https://doi.org/10.1093/annonc/mdw673.CrossRefPubMed

41.

Goldvaser H, Barnes TA, Šeruga B, Cescon DW, Ocaña A, Ribnikar D, Amir E. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2018;110(1). https://doi.org/10.1093/jnci/djx141.

42.

Honigberg MC, Zekavat SM, Aragam K, Finneran P, Klarin D, Bhatt DL, et al. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA. 2019;322(24):2411–21. https://doi.org/10.1001/jama.2019.19191.CrossRefPubMedCentralPubMed

43.

Secoșan C, Balint O, Pirtea L, Grigoraș D, Bălulescu L, Ilina R. Surgically induced menopause-a practical review of literature. Medicina (Kaunas). 2019;55(8):482. https://doi.org/10.3390/medicina55080482.CrossRefPubMed

44.

Duffy C, Allen S. Medical and psychosocial aspects of fertility after cancer. Cancer J. 2009;15(1):27–33. https://doi.org/10.1097/PPO.0b013e3181976602. PMID: 19197170; PMCID: PMC2719717.

45.

•• Mitchell JD, Cehic DA, Morgia M, Bergom C, Toohey J, Guerrero PA, et al. Cardiovascular manifestations from therapeutic radiation: a multidisciplinary expert consensus statement from the International Cardio-Oncology Society. JACC CardioOncol. 2021;3(3):360–80. https://doi.org/10.1016/j.jaccao.2021.06.003. Discusses short- and long-term cardiovascular effects of radiation therapy, disease prevention opportunities, practical recommendations for CVD screening and disease management.

46.

Amer MH. Genetic factors and breast cancer laterality. Cancer Manag Res. 2014;16(6):191–203. https://doi.org/10.2147/CMAR.S60006.CrossRef

47.

Liu E, Guan X, Wei R, Jiang Z, Liu Z, Wang G, et al. Association between radiotherapy and death from cardiovascular disease among patients with cancer: a large population-based cohort study. J Am Heart Assoc. 2022;11(6):e023802. https://doi.org/10.1161/JAHA.121.023802.

48.

•• Khalid Y, Fradley M, Dasu N, Dasu K, Shah A, Levine A. Gender disparity in cardiovascular mortality following radiation therapy for Hodgkin’s lymphoma: a systematic review. Cardiooncology. 2020;5(6):12. https://doi.org/10.1186/s40959-020-00067-7. Meta-analysis of 13,975 patients finding that female HL survivors have a higher rate of radiation-induced coronary artery disease than male survivors.

49.

Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B, Lacasce A, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood. 2011;117:412–8. https://doi.org/10.1182/blood-2010-06-291328.CrossRefPubMed

50.

•• Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–4361. https://doi.org/10.1093/eurheartj/ehac244. First European Society of Cardiology (ESC) guidelines on cardio-oncology, drafted to assist healthcare professionals in providing cardiovascular care to oncology patients before, during, and after cancer treatments.

51.

Bansal N, Blanco JG, Sharma UC, Pokharel S, Shisler S, Lipshultz SE. Cardiovascular diseases in survivors of childhood cancer. Cancer Metastasis Rev. 2020;39(1):55–68. https://doi.org/10.1007/s10555-020-09859-w.CrossRefPubMedCentralPubMed

52.

Cheng YJ, Nie XY, Ji CC, Lin XX, Liu LJ, Chen XM, et al. Long-term cardiovascular risk after radiotherapy in women with breast cancer. J Am Heart Assoc. 2017;6(5):e005633. https://doi.org/10.1161/JAHA.117.005633.

53.

Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–98. https://doi.org/10.1056/NEJMoa1209825. PMID: 23484825.CrossRefPubMed

54.

Carlson LE, Watt GP, Tonorezos ES, Chow EJ, Yu AF, Woods M, et al. WECARE Study Collaborative Group. Coronary artery disease in young women after radiation therapy for breast cancer: the WECARE study. JACC CardioOncol. 2021;3(3):381–392. https://doi.org/10.1016/j.jaccao.2021.07.008.

55.

Zureick AH, Grzywacz VP, Almahariq MF, Silverman BR, Vayntraub A, Chen PY, et al. Dose to the left anterior descending artery correlates with cardiac events after irradiation for breast cancer. Int J Radiat Oncol Biol Phys. 2022;114(1):130–9. https://doi.org/10.1016/j.ijrobp.2022.04.019.CrossRefPubMed

56.

Bates J, Chen MH, Constine L. Radiation-associated coronary disease in young cancer survivors: the beat goes on: we must preserve it. J Am Coll Cardiol CardioOnc. 2021;3(3):393–6. https://doi.org/10.1016/j.jaccao.2021.08.002.CrossRef

57.

Chen MH, Chuang ML, Bornstein BA, Gelman R, Harris JR, Manning WJ. Impact of respiratory maneuvers on cardiac volume within left breast radiation portals. Circulation. 1997;96:3269–72.CrossRefPubMed

58.

Lin A, Sharieff W, Juhasz J, Whelan T, Kim DH. The benefit of deep inspiration breath hold: evaluating cardiac radiation exposure in patients after mastectomy and after breast-conserving surgery. Breast Cancer. 2017;24(1):86–91. https://doi.org/10.1007/s12282-016-0676-5. Epub 2016 Feb 17.CrossRefPubMed

59.

Ratosa I, Ivanetic Pantar M. Cardiotoxicity of mediastinal radiotherapy. Rep Pract Oncol Radiother. 2019;24(6):629–643. https://doi.org/10.1016/j.rpor.2019.09.002.

60.

Baues C, Marnitz S, Engert A. Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation. Radiat Oncol. 2018;13:122.CrossRefPubMedCentralPubMed

61.

Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin’s disease: Report from the Late Effects Study Group. J Clin Oncol. 2003;21:4386–94.CrossRefPubMed

62.

Swerdlow AJ, Cooke R, Bates A, Cunningham D, Falk SJ, Gilson D, et al. Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin’s lymphoma in England and Wales: a national cohort study. J Clin Oncol. 2012;30(22):2745–2752.

63.

Armenian SH, Sun CL, Francisco L, Steinberger J, Kurian S, Wong FL, et al. Late congestive heart failure after hematopoietic cell transplantation. J Clin Oncol. 2008;26:5537–43. https://doi.org/10.1200/JCO.2008.17.742.CrossRefPubMedCentralPubMed

64.

Leger KJ, Cushing-Haugen K, Hansen JA, Fan W, Leisenring WM, Martin PJ, et al. Clinical and genetic determinants of cardiomyopathy risk among hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant. 2016;22(6):1094–101. https://doi.org/10.1016/j.bbmt.2016.02.017.CrossRefPubMedCentralPubMed

65.

Gender differences in pediatric hematopoietic stem cell transplantation (HSCT). Clinicaltrials.gov. Accessed June 5, 2023. https://clinicaltrials.gov/ct2/show/NCT04580576

66.

Alidina A, Lawrence D, Ford LA, Baer MR, Bambach B, Bernstein SH, et al. Thiotepa-associated cardiomyopathy during blood or marrow transplantation: association with the female sex and cardiac risk factors. Biol Blood Marrow Transplant. 1999;5(5):322–7. https://doi.org/10.1016/s1083-8791(99)70008-x. PMID: 10534063.CrossRefPubMed

67.

Haavisto A, Wettergren L, Lampic C, Lähteenmäki PM, Jahnukainen K. Premature ovarian insufficiency and chance of pregnancy after childhood cancer: a population-based study (the Fex-Can study). Int J Cancer. 2023;153(3):644–53. https://doi.org/10.1002/ijc.34541. Epub 2023 Apr 20.CrossRefPubMed

68.

Anagnostis P, Christou K, Artzouchaltzi AM, Gkekas NK, Kosmidou N, et al. Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis. Eur J Endocrinol. 2019;180(1):41–50. https://doi.org/10.1530/EJE-18-0602.CrossRefPubMed

69.

Duncan CN, Brazauskas R, Huang J, Shaw BE, Majhail NS, Savani BN. Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2018;53(10):1278–87. https://doi.org/10.1038/s41409-018-0155-z.CrossRefPubMedCentralPubMed

70.

Hilal L, Cercek A, Navilio J, Hsu M, Zhang Z, Brady P, et al. Factors associated with premature ovarian insufficiency in young women with locally advanced rectal cancer treated with pelvic radiation therapy. Adv Radiat Oncol. 2021;7(1):100801. https://doi.org/10.1016/j.adro.2021.100801.

71.

Craig F, Leiper AD, Stanhope R, Brain C, Meller ST, Nussey SS. Sexually dimorphic and radiation dose dependent effect of cranial irradiation on body mass index. Arch Dis Child. 1999;81(6):500–4. https://doi.org/10.1136/adc.81.6.500.CrossRefPubMedCentralPubMed

72.

• Mulrooney DA, Hyun G, Ness KK, Ehrhardt MJ, Yasui Y, Duprez D, et al. Major cardiac events for adult survivors of childhood cancer diagnosed between 1970 and 1999: report from the Childhood Cancer Survivor Study cohort. BMJ. 2020;368:l6794. https://doi.org/10.1136/bmj.l6794. Report on incidence of HF, CAD, and other cardiac diseases in 23,462 five-year survivors of childhood cancer treated in the 1970s, 1980s, and 1990s, showing decreased incidence of cardiac events over time.

73.

Lee JJ, Cook-Wiens G, Johnson BD, Braunstein GD, Berga SL, Stanczyk FZ, et al. Age at menarche and risk of cardiovascular disease outcomes: findings from the national heart lung and blood institute-sponsored women’s ischemia syndrome evaluation. J Am Heart Assoc. 2019;8(12):e012406. https://doi.org/10.1161/JAHA.119.012406.

74.

Armstrong GT, Whitton JA, Gajjar A, Kun LE, Chow EJ, Stovall M, Leisenring W, Robison LL, Sklar CA. Abnormal timing of menarche in survivors of central nervous system tumors: a report from the Childhood Cancer Survivor Study. Cancer. 2009;115(11):2562–70. https://doi.org/10.1002/cncr.24294.CrossRefPubMed

75.

Fuhrman BJ, Moore SC, Byrne C, Makhoul I, Kitahara CM, Berrington de González A, et al. Association of the age at menarche with site-specific cancer risks in pooled data from nine cohorts. Cancer Res. 2021;81(8):2246–2255. https://doi.org/10.1158/0008-5472.CAN-19-3093.

76.

Cooke R, Jones ME, Cunningham D, Falk SJ, Gilson D, Hancock BW, et al. England and Wales Hodgkin Lymphoma Follow-up Group; Swerdlow AJ. Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors. Br J Cancer. 2013;108(11):2399–406. https://doi.org/10.1038/bjc.2013.219. Epub 2013 May 7.

77.

Honigberg MC, Sarma AA. Pregnancy among survivors of childhood cancer: cardiovascular considerations. Curr Treat Options Cardiovasc Med. 2018;20(7):54. https://doi.org/10.1007/s11936-018-0650-y. PMID: 29923132.CrossRefPubMed

78.

Nolan M, Oikonomou EK, Silversides CK, Hines MR, Thompson KA, Campbell BA, et al. Impact of cancer therapy-related cardiac dysfunction on risk of heart failure in pregnancy. JACC CardioOncol. 2020;2(2):153–62. https://doi.org/10.1016/j.jaccao.2020.04.007.CrossRefPubMedCentralPubMed

79.

Intapad S, Alexander BT. Pregnancy complications and later development of hypertension. Curr Cardiovasc Risk Rep. 2013;7(3):183–9. https://doi.org/10.1007/s12170-013-0303-3.CrossRefPubMedCentralPubMed

80.

Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, et al. ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165–3241. https://doi.org/10.1093/eurheartj/ehy340.

81.

Armenian SH, Hudson MM, Mulder RL, Chen MH, Constine LS, Dwyer M, et al. International Late Effects of Childhood Cancer Guideline Harmonization Group. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015;16(3):e123–36. https://doi.org/10.1016/S1470-2045(14)70409-7.

82.

Sklar CA, Mertens AC, Mitby P, Whitton J, Stovall M, et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst. 2006;98(13):890–6. https://doi.org/10.1093/jnci/djj243.CrossRefPubMed

83.

Swerdlow AJ, Cooke R, Bates A, Cunningham D, Falk SJ, et al. England and Wales Hodgkin Lymphoma Follow-up Group. Risk of premature menopause after treatment for Hodgkin’s lymphoma. J Natl Cancer Inst. 2014;106(9):dju207. https://doi.org/10.1093/jnci/dju207.

84.

Shin J, Han K, Jung JH, Park HJ, Kim W, Huh Y, et al. Age at menopause and risk of heart failure and atrial fibrillation: a nationwide cohort study. Eur Heart J. 2022;43(40):4148–57. https://doi.org/10.1093/eurheartj/ehac364.CrossRefPubMed

85.

Freaney PM, Ning H, Carnethon M, Allen NB, Wilkins J, Lloyd-Jones DM, Khan SS. Premature menopause and 10-year risk prediction of atherosclerotic cardiovascular disease. JAMA Cardiol. 2021;6(12):1463–5. https://doi.org/10.1001/jamacardio.2021.3490.CrossRefPubMedCentralPubMed

86.

Manson JE, Woodruff TK. Reproductive health as a marker of subsequent cardiovascular disease: the role of estrogen. JAMA Cardiol. 2016;1:776–7.CrossRefPubMedCentralPubMed

87.

Yoshida Y, Chen Z, Baudier RL, Krousel-Wood M, Anderson AH, Fonseca VA, Mauvais-Jarvis F. Early menopause and cardiovascular disease risk in women with or without type 2 diabetes: a pooled analysis of 9,374 postmenopausal women. Diabetes Care. 2021;44(11):2564–72. https://doi.org/10.2337/dc21-1107.CrossRefPubMedCentralPubMed

88.

Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the women’s health initiative observational study. JAMA. 2002;288(8):980–7. https://doi.org/10.1001/jama.288.8.980.CrossRefPubMed

89.

Oliver-Williams C, Glisic M, Shahzad S, Brown E, Pellegrino Baena C, Chadni M, et al. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review. Hum Reprod Update. 2019;25(2):257–71. https://doi.org/10.1093/humupd/dmy039.CrossRefPubMed

90.

Moadel, AB. Psychological distress of prematurely menopausal cancer survivors. Dissertation Abstracts International, Volume: 57–03, Section: B, page: 2210. 1995. https://repository.yu.edu/handle/20.500.12202/3654.

91.

Celano CM, Villegas AC, Albanese AM, Gaggin HK, Huffman JC. Depression and anxiety in heart failure: a review. Harv Rev Psychiatry. 2018;26(4):175–184. https://doi.org/10.1097/HRP.0000000000000162.

92.

• Koop Y, van Zadelhof N, Maas AHEM, Atsma F, El Messaoudi S, Vermeulen H. Quality of life in breast cancer patients with cancer treatment-related cardiac dysfunction: a qualitative study. Eur J Cardiovasc Nurs. 2022;21(3):235–42. https://doi.org/10.1093/eurjcn/zvab057. Insights into the impact of cancer therapy-related cardiac dysfunction on quality of life in breast cancer survivors. Highlights physical, social, and psychological challenges requiring a holistic, multidisciplinary approach to treatment.

93.

Macdonald S, Blane D, Browne S, Conway E, Macleod U, May C, Mair F. Illness identity as an important component of candidacy: contrasting experiences of help-seeking and access to care in cancer and heart disease. Soc Sci Med. 2016;168:101–10. https://doi.org/10.1016/j.socscimed.2016.08.022.CrossRefPubMed

94.

Kirchhoff AC, Yi J, Wright J, Warner EL, Smith KR. Marriage and divorce among young adult cancer survivors. J Cancer Surviv. 2012;6(4):441–50. https://doi.org/10.1007/s11764-012-0238-6.CrossRefPubMedCentralPubMed

95.

Glantz MJ, Chamberlain MC, Liu Q, Hsieh CC, Edwards KR, Van Horn A, Recht L. Gender disparity in the rate of partner abandonment in patients with serious medical illness. Cancer. 2009;115(22):5237–42. https://doi.org/10.1002/cncr.24577.CrossRefPubMed

96.

Lee MK, Yun YH. Working situation of cancer survivors versus the general population. J Cancer Surviv. 2015;9(2):349–60. https://doi.org/10.1007/s11764-014-0418-7.CrossRefPubMed

97.

Rabinowitz B. Psychosocial issues in breast cancer. Obstet Gynecol Clin North Am. 2002;29:233–47.CrossRefPubMed

98.

Monti DA, Mago R, Kunkel EJS. Practical geriatrics: depression, cognition, and anxiety among postmenopausal women with breast cancer. Psychiatr Serv. 2005;56(11):1353–5. https://doi.org/10.1176/appi.ps.56.11.1353.CrossRefPubMed

99.

van Leeuwen M, Husson O, Alberti P, Arraras JI, Chinot OL, Costantini A, et al.; EORTC QLG. Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire. Health Qual Life Outcomes. 2018;16(1):114. https://doi.org/10.1186/s12955-018-0920-0.

100.

Kreutz C, Schmidt ME, Steindorf K. Effects of physical and mind-body exercise on sleep problems during and after breast cancer treatment: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019;176:1–15. https://doi.org/10.1007/s10549-019-05217-9.CrossRefPubMed

101.

Jean-Louis G, Zizi F, Clark LT, Brown CD, McFarlane SI. Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components. J Clin Sleep Med. 2008;4(3):261–72.CrossRefPubMedCentralPubMed

102.

Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, et al; American Heart Association Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Peripheral Vascular Disease. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. Circulation. 2019;139(21):e997-e1012. https://doi.org/10.1161/CIR.0000000000000679.

103.

Jones LW, Liu Q, Armstrong GT, Ness KK, Yasui Y, Devine K, et al. Exercise and risk of major cardiovascular events in adult survivors of childhood hodgkin lymphoma: a report from the childhood cancer survivor study. J Clin Oncol. 2014;32(32):3643–50. https://doi.org/10.1200/JCO.2014.56.7511.CrossRefPubMedCentralPubMed

104.

Jones LW, Habel LA, Weltzien E, Castillo A, Gupta D, Kroenke CH, et al. Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer. J Clin Oncol. 2016;34(23):2743–9. https://doi.org/10.1200/JCO.2015.65.6603.CrossRefPubMedCentralPubMed

105.

Dittus KL, Lakoski SG, Savage PD, Kokinda N, Toth M, Stevens D, et al. Exercise-based oncology rehabilitation: leveraging the cardiac rehabilitation model. J Cardiopulm Rehabil Prev. 2015;35(2):130–9. https://doi.org/10.1097/HCR.0000000000000091.

106.

• Ligibel JA, Bohlke K, May AM, Clinton SK, Demark-Wahnefried W, Gilchrist SC, et al. Exercise, diet, and weight management during cancer treatment: ASCO Guideline. J Clin Oncol. 2022;40(22):2491–507. https://doi.org/10.1200/JCO.22.00687. First-ever American Society of Clinical Oncology exercise guidelines for adults in active cancer treatment.

107.

• Khadanga S, Gaalema DE, Savage P, Ades PA. Underutilization of cardiac rehabilitation in women: barriers and solutions. J Cardiopulm Rehabil Prev. 2021;41(4):207–13. https://doi.org/10.1097/HCR.0000000000000629. PMID:34158454; PMCID:PMC8243714. Highlights physical and psychosocial barriers to female participation in cardiac rehabilitation.

108.

Chesler RM. Goldberg N & Stein RA Physiologic considerations and pragmatic issues in the design and implementation of lifetime exercise programs to prevent and treat coronary artery disease in women. Curr Cardio Risk Rep. 2009;3:211–8. https://doi.org/10.1007/s12170-009-0033-8.CrossRef

109.

Savage PD, Sanderson BK, Brown TM, Berra K, Ades PA. Clinical research in cardiac rehabilitation and secondary prevention: looking back and moving forward. J Cardiopulm Rehabil Prev. 2011;31(6):333–41. https://doi.org/10.1097/HCR.0b013e31822f0f79.

110.

Moore SM, Kramer FM. Women’s and men’s preferences for cardiac rehabilitation program features. J Cardiopulm Rehabil. 1996;16(3):163–8. https://doi.org/10.1097/00008483-199605000-00003.

111.

Grace SL, Gravely-Witte S, Kayaniyil S, Brual J, Suskin N, Stewart DE. A multisite examination of sex differences in cardiac rehabilitation barriers by participation status. J Womens Health (Larchmt). 2009;18(2):209–16. https://doi.org/10.1089/jwh.2007.0753.CrossRefPubMed

112.

Bhatt DL. Birth and maturation of cardio-oncology. JACC CardioOncol. 2019;1(1):114–6. https://doi.org/10.1016/j.jaccao.2019.08.004.CrossRefPubMedCentralPubMed

113.

Ahmad J, Muthyala A, Kumar A, Dani SS, Ganatra S. Disparities in cardio-oncology: effects on outcomes and opportunities for improvement. Curr Cardiol Rep. 2022;24(9):1117–27. https://doi.org/10.1007/s11886-022-01732-2.CrossRefPubMedCentralPubMed

114.

Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al.; ESMO Guidelines Committee. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–190. https://doi.org/10.1016/j.annonc.2019.10.023.

115.

Shanmuganathan JWD, Kragholm K, Tayal B, Polcwiartek C, Poulsen LØ, El-Galaly TC, et al. Risk for myocardial infarction following 5-fluorouracil treatment in patients with gastrointestinal cancer: a nationwide registry-based study. JACC CardioOncol. 2021;3(5):725–33. https://doi.org/10.1016/j.jaccao.2021.11.001.CrossRefPubMedCentralPubMed

116.

Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer. 2005;103(6):1165–71. https://doi.org/10.1002/cncr.20878.CrossRefPubMed

117.

Totzeck M, Mincu RI, Rassaf T. Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20 000 patients. J Am Heart Assoc. 2017;6(8):e006278. https://doi.org/10.1161/JAHA.117.006278.

118.

Brahmer JR, Dahlberg SE, Gray RJ, Schiller JH, Perry MC, Sandler A, Johnson DH. Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599. J Thorac Oncol. 2011;6(1):103–8. https://doi.org/10.1097/JTO.0b013e3181fa8efd.CrossRefPubMedCentralPubMed

119.

Imai A, Ichigo S, Matsunami K, Takagi H, Kawabata I. Ovarian function following targeted anti-angiogenic therapy with bevacizumab. Mol Clin Oncol. 2017;6(6):807–810. https://doi.org/10.3892/mco.2017.1237. Epub 2017 May 5. PMID: 28588768; PMCID: PMC5451849.

120.

Chmielewski NN, Limoli CL. Sex differences in taxane toxicities. Cancers (Basel). 2022;14(14):3325. https://doi.org/10.3390/cancers14143325.CrossRefPubMed

121.

Winters-Stone KM, Horak F, Jacobs PG, Trubowitz P, Dieckmann NF, Stoyles S, Faithfull S. Falls, Functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy. J Clin Oncol. 2017;35(23):2604–12. https://doi.org/10.1200/JCO.2016.71.3552.CrossRefPubMedCentralPubMed

122.

van der Veldt AA, Boven E, Helgason HH, van Wouwe M, Berkhof J, de Gast G, Mallo H, Tillier CN, van den Eertwegh AJ, Haanen JB. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer. 2008;99(2):259–65. https://doi.org/10.1038/sj.bjc.6604456.CrossRefPubMedCentralPubMed

123.

Harvey PA, Leinwand LA. Oestrogen enhances cardiotoxicity induced by Sunitinib by regulation of drug transport and metabolism. Cardiovasc Res. 2015;107(1):66–77. https://doi.org/10.1093/cvr/cvv152. Epub 2015 May 25. PMID: 26009590; PMCID: PMC4560048.

Titel: Tailored to a Woman’s Heart: Gender Cardio-Oncology Across the Lifespan
verfasst von: Ming Hui Chen
Sonia F. Epstein
Publikationsdatum: 11.10.2023
Verlag: Springer US
Erschienen in: Current Cardiology Reports / Ausgabe 11/2023
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-023-01967-7

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Tailored to a Woman’s Heart: Gender Cardio-Oncology Across the Lifespan

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2023

The Evolving Paradigm of Revascularization in Ischemic Cardiomyopathy: from Recovery of Systolic Function to Protection Against Future Ischemic Events

Genetic Engineering of Donor Pig for the First Human Cardiac Xenotransplantation: Combatting Rejection, Coagulopathy, Inflammation, and Excessive Growth

Using Patient Decision Aids for Cardiology Care in Diverse Populations

Computed Tomography–Guided Pericardiocentesis: A Practical Guide

Long-Term Remote vs. Conventional Monitoring of Pacemakers: Systematic Review and Meta-Analysis of Randomized Controlled Trials

Indications for Cardiac Catheterization and Percutaneous Coronary Intervention in Patients with Resuscitated Out-of-Hospital Cardiac Arrest

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie